title: Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design.
abstract: In cooperation with the fragment-based design a new drug design method, the so-called "fragment-based quantitative structure-activity relationship" (FB-QSAR) is proposed. The essence of the new method is that the molecular framework in a family of drug candidates are divided into several fragments according to their substitutes being investigated. The bioactivities of molecules are correlated with the physicochemical properties of the molecular fragments through two sets of coefficients in the linear free energy equations. One coefficient set is for the physicochemical properties and the other for the weight factors of the molecular fragments. Meanwhile, an iterative double least square (IDLS) technique is developed to solve the two sets of coefficients in a training data set alternately and iteratively. The IDLS technique is a feedback procedure with machine learning ability. The standard Two-dimensional quantitative structure-activity relationship (2D-QSAR) is a special case, in the FB-QSAR, when the whole molecule is treated as one entity. The FB-QSAR approach can remarkably enhance the predictive power and provide more structural insights into rational drug design. As an example, the FB-QSAR is applied to build a predictive model of neuraminidase inhibitors for drug development against H5N1 influenza virus.
authors.affiliation: College of Life Science and Technology, Guangxi University, Nanning, Guangxi, 530004, China. duqishi@yahoo.com
authors.forename: Qi-Shi
authors.initials: QS
authors.lastname: Du
authors.forename: Ri-Bo
authors.initials: RB
authors.lastname: Huang
authors.forename: Yu-Tuo
authors.initials: YT
authors.lastname: Wei
authors.forename: Zong-Wen
authors.initials: ZW
authors.lastname: Pang
authors.forename: Li-Qin
authors.initials: LQ
authors.lastname: Du
authors.forename: Kuo-Chen
authors.initials: KC
authors.lastname: Chou
mesh_terms: D000818:Animals; D000998:Antiviral Agents; D015195:Drug Design; D053124:Influenza A Virus, H5N1 Subtype / Q000187:drug effects; D008962:Models, Theoretical; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D009975:Orthomyxoviridae / Q000378:metabolism; D021281:Quantitative Structure-Activity Relationship
chemical_list: D000998:Antiviral Agents; D009439:Neuraminidase